BeiGene gearing up for PD-1 competition with Merck, Innovent in 1L squamous NSCLC in China

BeiGene announced Tuesday that tislelizumab met the primary endpoint in a Chinese Phase III trial for first-line squamous non-small cell lung cancer. The readout keeps BeiGene’s PD-1 mAb on track as it vies with Innovent’s Tyvyt to become the second approved in China for the indication behind Keytruda.

In an interim analysis by an independent review committee, first-line tislelizumab reached a pre-specified threshold for improving progression-free survival, the primary endpoint in the Phase III BGB-A317-307 trial. The open-label study compared tislelizumab plus carboplatin in combination with paclitaxel or Abraxane nab-paclitaxel with chemotherapy alone...